ESC 365 - Silent cerebral microvascular disease and longitudinal risk of cognitive decline in atrial fibrillation

ESC Professional Premium Access

Silent cerebral microvascular disease and longitudinal risk of cognitive decline in atrial fibrillation

Session: Antithrombotic and anticoagulant therapy in special populations

Topic: Anticoagulants

Speaker: Associate Professor Y. Kondo (Chiba, JP)

Event: ESC Congress 2024

Congress Presentation

Add to my library

About the speaker

Associate Professor Yusuke Kondo

Chiba University Graduate School of Medicine, Chiba (Japan)

1 follower

8 more presentations in this session

Direct oral anticoagulants exhibit lower risks of mortality and bleeding compared to vitamin-k antagonists in atrial fibrillation patients on chronic hemodialysis: a meta-analysis

Speaker: Doctor H. Jain (Jodhpur, IN)

Medication adherence and antithrombotic therapy outcomes: insights from a post-hoc analysis of the AFIRE trial

Speaker: Doctor N. Chiba (Sendai, JP)

Impact of differences in body mass index, body surface area and lean body mass on clinical outcomes in patients with atrial fibrillation receiving edoxaban: 4-year follow-up data from ETNA-AF-Europe

Speaker: Professor G. Boriani (Modena, IT)

Haemorrhagic risk in elderly patients with atrial fibrillation that develop low platelet count during direct oral anticoagulant treatment: insights from the ATHERO-AF study.

Speaker: Doctor D. Menichelli (Rome, IT)

The role of anticoagulation in atrial high-rate episodes: a meta-analysis

Speaker: Doctor H. Ahmed (Omaha, US)

Access the full session

Antithrombotic and anticoagulant therapy in special populations

Speakers: Associate Professor Y. Kondo, Doctor H. Jain, Doctor N. Chiba, Professor G. Boriani, Doctor D. Menichelli...

About the event

ESC Congress 2024

30 August - 2 September 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources